Established in 2009, Retrogenix provides the world’s leading solution for identifying the specific primary receptors and any off-targets for biologics, cell therapies, and small molecules. Our proprietary cell microarray technology has provided key specificity data for lead selection and regulatory applications for 1,000’s of test molecules.

The unique platform screens test molecules against the largest commercially available human protein library, containing 6,200+ plasma membrane proteins, secreted proteins, and heterodimeric plasma membrane protein complexes, all expressed in human cells.

Retrogenix works with all of the top 20 global pharmaceutical companies, 100’s of biotechnology companies, and leading research institutions worldwide, to accelerate and de-risk drug discovery programs. Our results are widely published in high impact journals, such as Nature, Molecular Cancer, Cancer Cell, mBio and Oncotarget.

Retrogenix has been used in many successful IND and BLA submissions worldwide. The data can replace tissue cross-reactivity studies, and are accepted by PMDA, FDA, EMA, and NMPA.

Learn more about Retrogenix data in regulatory submissions.

Retrogenix studies have:

  • High success rates
  • Very low incidence of false positives
  • Rapid turnaround times
  • High degree of sensitivity and specificity, even for low affinity interactions

Types of molecules screened:

  • Antibodies (monospecific, bispecific, multispecific)
  • ADCs
  • Nanoparticle
  • CAR-T Cells & scFvs
  • Peptides & proteins
  • Fabs, DARPins
  • Small Molecules
  • RNA
  • Viruses & virus-like particles

In 2015, Retrogenix won the Queen’s Award for Enterprise – the UK’s most prestigious business accolade – in recognition of its innovative work in developing and commercialising the cell microarray technology. This was followed in 2017 by a second Queen’s Award for outstanding achievements in international trade.

Members of our team are regularly invited to present at international events, and we frequently attend conferences, such as BioJapan, CAR-TCR Summit Asia, BioKorea, PEGS, SOT, ASGCT, ChinaBio.

Retrogenix is headquartered in the High Peak, UK, and all project work is undertaken by highly skilled scientists in our specialist laboratory facilities on-site in the UK. The company also has offices in Cambridge, MA, and Tsukuba, Japan. Retrogenix continues to build on its global reputation and the team is rapidly expanding to keep pace with demand for its services.

To find out more about study types, timelines, and costs, please get in touch.

Find out more:

Connect with us:

T. +44 (0)1663 732520



Retrogenix Limited

High Peak Business Park, Buxton Road
Chinley, High Peak
SK23 6FJ

Retrogenix Limited (Japan)


Get In Touch

    Simcere logo
    Aveo Oncology - The Human Response
    Theraclone Sciences
    Bluebird Bio
    The Center for Infectious Disease Research
    Compugen Logo
    Sanofi Logo
    The University of Copenhagen
    Lund University
    NIH - National Institutes of Health
    The University of Pennsylvania
    Scripps Florida - The Scripps Research Institute
    Peptinnovate Ltd - Unlocking Nature's Potential
    The University of Sheffield
    Capella Bioscience Logo
    Unum Theraputics Logo
    Celyad Logo
    Genmab Logo
    Molecular Partners Logo
    NanoMab Logo


    Find out what our customers say:

    …there was "no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool.
    Assistant Professor Thomas Lavstsen, University of Copenhagen. Quoted in BioWorld Today, June 2013